Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Gelmon

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 1998
The fine points of end points: phase II trials in lung cancerK A Gelmon
Seminars in Oncology|October 1, 1994
Biweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancerK A Gelmon
Seminars in Oncology|October 1, 1995
Biweekly paclitaxel in the treatment of patients with metastatic breast cancerK A Gelmon
Seminars in Oncology|June 1, 1995
Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancerS E O'Reilly, K A Gelmon
Seminars in Oncology|August 1, 1995
Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancerA W Tolcher, K A Gelmon
The Medical Journal of Australia|May 6, 1996
Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcomaJ L Millar, D Goldstein, K A Gelmon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2009
Breast carcinoma--rare types: review of the literatureR Yerushalmi, M M Hayes, K A Gelmon
Journal of the National Cancer Institute|November 8, 2001
Effect of news media coverage of cancer risk on clinical oncology practiceC W Lee, L Weir, K A Gelmon
Lancet (London, England)|September 23, 1989
Intermittent high-dose zidovudineL A Price, B T Hill, K A Gelmon
Current Oncology (Toronto, Ont.)|November 13, 2012
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artM Clemons, K A Gelmon, K I Pritchard, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 1998
The fine points of end points: phase II trials in lung cancerK A Gelmon
Seminars in Oncology|October 1, 1994
Biweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancerK A Gelmon
Seminars in Oncology|October 1, 1995
Biweekly paclitaxel in the treatment of patients with metastatic breast cancerK A Gelmon
Seminars in Oncology|June 1, 1995
Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancerS E O'Reilly, K A Gelmon
Seminars in Oncology|August 1, 1995
Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancerA W Tolcher, K A Gelmon
The Medical Journal of Australia|May 6, 1996
Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcomaJ L Millar, D Goldstein, K A Gelmon
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2009
Breast carcinoma--rare types: review of the literatureR Yerushalmi, M M Hayes, K A Gelmon
Journal of the National Cancer Institute|November 8, 2001
Effect of news media coverage of cancer risk on clinical oncology practiceC W Lee, L Weir, K A Gelmon
Lancet (London, England)|September 23, 1989
Intermittent high-dose zidovudineL A Price, B T Hill, K A Gelmon
Current Oncology (Toronto, Ont.)|November 13, 2012
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the artM Clemons, K A Gelmon, K I Pritchard, et al.
Pageof 6